Joint Research with The University of Tokyo Hospital and the Pharma Valley Project
First written in FY2016. 16 of 17 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「In addition, to generate the aforementioned next-generation compounds, the company is conducting joint research with The University of Tokyo Hospital and the Pharma Valley Project (Fujinokuni Medical Castle Promotion Organization, a general incorporated foundation, and University of Shizuoka).」
The company continues its joint research with The University of Tokyo Hospital, the Pharma Valley Project and University of Shizuoka. - FY2024RestatedAnnual report
「The company is also conducting joint research with the University of Tokyo Hospital and the Pharma Valley Project (Fujinokuni Medical Castle Town Promotion Organization and Shizuoka Prefectural University) to create next-generation compounds as described above.」
The company continues joint research with the University of Tokyo Hospital, the Pharma Valley Project and Shizuoka Prefectural University. - FY2024-Q3RestatedAnnual report
「The company is conducting exploratory research to create new candidate compounds and expand its development pipeline, including IDO/TDO inhibitors being optimized through joint research with Shizuoka Prefectural University.」
The company continues exploratory research, including joint research with Shizuoka Prefectural University. - FY2024-Q1RestatedAnnual report
「We are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues exploratory research, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2023RestatedAnnual report
「The company is also conducting joint research with the University of Tokyo Hospital and the Pharma Valley Project (Fujinokuni Medical Castle Town Promotion Organization and Shizuoka Prefectural University) to create next-generation compounds as described above.」
The company continues joint research with the University of Tokyo Hospital, the Pharma Valley Project and Shizuoka Prefectural University. - FY2023-Q3RestatedAnnual report
「We are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues exploratory research, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2023-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues exploratory research, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2022RestatedAnnual report
「The company is also conducting joint research with the University of Tokyo Hospital and the Pharma Valley Project (Fujinokuni Medical Castle Town Promotion Organization and Shizuoka Prefectural University) to create next-generation compounds as described above.」
The company continues joint research with the University of Tokyo Hospital, the Pharma Valley Project and Shizuoka Prefectural University. - FY2022-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues exploratory research, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2022-Q2RestatedAnnual report
「We are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues exploratory research, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2021RestatedAnnual report
「The company is also conducting joint research with the University of Tokyo Hospital and the Pharma Valley Project (Fujinokuni Medical Castle Town Promotion Organization and Shizuoka Prefectural University) to create next-generation compounds as described above.」
The company continues joint research with the University of Tokyo Hospital, the Pharma Valley Project and Shizuoka Prefectural University. - FY2021-Q3RestatedAnnual report
「The company is conducting exploratory research to create new candidate compounds and expand its development pipeline, including IDO/TDO inhibitors being optimized through joint research with Shizuoka Prefectural University.」
The company continues exploratory research, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2021-Q2RestatedAnnual report
「The company is conducting exploratory research to create new candidate compounds and expand its development pipeline, including IDO/TDO inhibitors being optimized through joint research with Shizuoka Prefectural University.」
The company continues exploratory research, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2021-Q1RestatedAnnual report
「The company is conducting exploratory research to create new candidate compounds and expand its development pipeline, including IDO/TDO inhibitors being optimized through joint research with Shizuoka Prefectural University.」
The company continues joint research activities, including the optimization of IDO/TDO inhibitors through joint research with Shizuoka Prefectural University. - FY2020RestatedAnnual report
「The company is also conducting joint research with the University of Tokyo Hospital, the Pharma Valley Project (Fujinokuni Medical Castle Town Promotion Organization and Shizuoka Prefectural University), and FUJIFILM Corporation to create next-generation compounds as described above.」
The company continues joint research with the University of Tokyo Hospital, the Pharma Valley Project and FUJIFILM. - FY2017RestatedAnnual report
「As described above, the company is also conducting joint research with the University of Tokyo Hospital, the Pharma Valley Project (Shizuoka Industrial Promotion Foundation and Shizuoka Prefectural University), and FUJIFILM Corporation.」
The company continues joint research with the University of Tokyo Hospital and the Pharma Valley Project. New joint research with FUJIFILM will be recorded in a separate thread. - FY2016First statedAnnual report
「As part of these activities, the company began joint research during the current fiscal year with the University of Tokyo Hospital, a national university corporation, to conduct efficacy studies of CBP501 using a mouse model of pancreatic cancer, and with the Pharma Valley Project (Shizuoka Industrial Promotion Foundation) to conduct drug discovery screening using a compound library.」
The company began 2 joint research projects in 2016 to conduct efficacy studies of CBP501 and screening using a compound library.